PT  - JOURNAL ARTICLE
AU  - Erwin B. Montgomery, Jr.
TI  - Two advances in the management of Parkinson disease
DP  - 2002 Aug 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 639--643
VI  - 69
IP  - 8
4099  - http://www.ccjm.org/content/69/8/639.short
4100  - http://www.ccjm.org/content/69/8/639.full
SO  - Cleve Clin J Med2002 Aug 01; 69
AB  - Levodopa should generally be avoided early in the course of Parkinson disease; dopamine agonists, particularly second-generation agents such as ropinirole (Requip) and pramipexole (Mirapex), carry a smaller long-term risk of dyskinesia and should be used instead. Deep brain stimulation is remarkably effective in refractory cases and may well usher in a new era in the treatment of chronic neurologic disease.